Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Medicis Pharmaceutical (NYSE:MRX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Reports
Recent Events
Aug 23Earnings Announcement
Location
8125 North Hayden Road
Scottsdale, AZ 85258
Phone: (602) 808-8800
Fax: (602) 808-0822
Email: info@medicis.com
Employees (last reported count): 172
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 600 SmallCap
Ownership
·Insider and 5%+ Owners: 38%
·Over the last 6 months:
 · 3 insider sells; 17.0K shares
  (0.1% of insider shares)
·Institutional: 92% (149% of float)
(438 institutions)
·Net Inst. Buying: 399.0K shares (+1.41%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Medicis Pharmaceutical is a specialty pharmaceutical company and an independent pharmaceutical company in the United States focusing primarily on the treatment of dermatological conditions. The Company offers prescription products and an over-the-counter (OTC) product. Medicis develops and markets products for major segments within dermatology, including acne, rosacea, antifungals, eczema, hyperpigmentation, pediculosis (head lice), psoriasis, seborrheic dermatitis and cosmesis (improvement in the texture and appearance of skin). The Company's primary products include the prescription brands Dynacin (minocycline HCl), Triza (benzoyl peroxide), Loprox (ciclopirox), Lustra and Lustra-AF (hydroquinone), Ovide (malathion), Plexion (sodium sulfacetamide/sulfur), Lidex (fluocinonide), Synalar (fluocinolone acetonide), Topicort (desoximetasone), Buphenyl (sodium phenylbutyrate), a prescription product indicated in the treatment of Urea Cycle Disorder, and the OTC brand Esoterica.
More from Market Guide: Expanded Business Description

Financial Summary
Medicis is an independent pharmaceutical company that offers prescription and over-the-counter products to treat a number of dermatological conditions. For the fiscal year ended 6/30/01, net sales increased 21% to $167.8 million. Net income decreased 6% to $40.4 million. Revenues reflect higher sales of DYNACIN(R), TRIAZ(R) and PLEXION(R). Earnings were offset by a $17.8 million special charge for a research and development collaboration with Corixa Corp.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Jonah Shacknai, 43
Chairman, CEO
$1.0M$10M
Mark Prygocki, Sr., 34
CFO, Exec. VP, Treasurer, Sec.
480K62K
Richard Havens
Exec. VP of Sales and Marketing
--  --  
Joseph Cooper
Exec. VP, Bus. Devel.
--  --  
Mitchell Wortzman, Ph.D.
Exec. VP, R&D
--  --  
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NYSE:MRXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$31.00 
Recent Price$49.11 
52-Week High
on 24-Oct-2000
$76.00 
Beta0.95 
Daily Volume (3-month avg)199.1K
Daily Volume (10-day avg)286.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-26.4%
52-Week Change
relative to S&P500
-1.3%
Share-Related Items
Market Capitalization$1.48B
Shares Outstanding30.2M
Float18.7M
Dividends & Splits
Annual Dividendnone 
Last Split: 3 for 2 on 17-Feb-1999
Per-Share Data
Book Value (mrq)$16.67 
Earnings (ttm)$1.27 
Earnings (mrq)$0.44 
Sales (ttm)$5.29 
Cash (mrq)$11.06 
Valuation Ratios
Price/Book (mrq)2.95 
Price/Earnings (ttm)38.61 
Price/Sales (ttm)9.29 
Income Statements
Sales (ttm)$167.8M
EBITDA (ttm)$52.1M
Income available to common (ttm)$40.4M
Profitability
Profit Margin (ttm)24.1%
Operating Margin (ttm)26.1%
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)7.80%
Return on Equity (ttm)8.55%
Financial Strength
Current Ratio (mrq)9.87 
Debt/Equity (mrq)0 
Total Cash (mrq)$334.2M
Short Interest
As of 8-Aug-2001
Shares Short740.0K
Percent of Float4.0%
Shares Short
(Prior Month)
789.0K
Short Ratio3.39 
Daily Volume218.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.